Telix Pharmaceuticals (TLX) Assets (2023 - 2025)

Telix Pharmaceuticals (TLX) has 3 years of Assets data on file, last reported at $1.2 billion in Q4 2025.

• Assets for Q4 2025 came in at $1.2 billion, up 17.38% year-over-year; the trailing twelve-month figure through Dec 2024 was $991.7 million (up 275.25% YoY), and the FY2025 annual result was $1.2 billion, up 17.38% from the prior year.
• Assets rose to $1.2 billion in Q4 2025 per TLX's latest filing, from $991.7 million in the prior quarter.
• Over five years, Assets peaked at $1.2 billion in Q4 2025 and troughed at $264.3 million in Q4 2023.
• A 3-year average of $806.6 million and a median of $991.7 million in 2024 frame the typical range for Assets.
• The sharpest annual moves came in 2024 and 2025: Assets surged 275.25% in 2024, then advanced 17.38% in 2025.
• A 3-year view of Assets shows it stood at $264.3 million in 2023, then surged by 275.25% to $991.7 million in 2024, then grew by 17.38% to $1.2 billion in 2025.
• Business Quant data shows TLX's Assets at $1.2 billion in Q4 2025, $991.7 million in Q4 2024, and $264.3 million in Q4 2023.